Forte Biosciences, Inc. (FBRX)
76.99
0.00 (0.00%)
USD |
NASDAQ |
Sep 01, 16:00
Forte Biosciences Cash from Operations (TTM) : -71.98M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -71.98M |
| March 31, 2026 | -59.34M |
| December 31, 2025 | -50.88M |
| September 30, 2025 | -44.42M |
| June 30, 2025 | -38.56M |
| March 31, 2025 | -34.43M |
| December 31, 2024 | -30.74M |
| September 30, 2024 | -29.70M |
| June 30, 2024 | -30.63M |
| March 31, 2024 | -30.17M |
| December 31, 2023 | -28.71M |
| September 30, 2023 | -22.63M |
| June 30, 2023 | -15.51M |
| March 31, 2023 | -11.41M |
| December 31, 2022 | -8.185M |
| September 30, 2022 | -8.874M |
| June 30, 2022 | -12.06M |
| March 31, 2022 | -14.62M |
| Date | Value |
|---|---|
| December 31, 2021 | -16.68M |
| September 30, 2021 | -16.90M |
| June 30, 2021 | -19.51M |
| March 31, 2021 | -19.59M |
| December 31, 2020 | -18.42M |
| September 30, 2020 | -15.27M |
| June 30, 2020 | -8.087M |
| March 31, 2020 | 12.05M |
| December 31, 2019 | -2.771M |
| September 30, 2019 | -14.06M |
| June 30, 2019 | -12.56M |
| March 31, 2019 | -39.44M |
| December 31, 2018 | -34.47M |
| September 30, 2018 | -31.70M |
| June 30, 2018 | -39.68M |
| March 31, 2018 | -36.27M |
| December 31, 2017 | -31.13M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| argenx SE | 1.160B |
| ACADIA Pharmaceuticals, Inc. | 160.32M |
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| Anika Therapeutics, Inc. | 5.977M |
| Savara, Inc. | -110.38M |